Right buddy, temp CEO with an M&A background in place for nine months, blackout period going on three weeks now, several members of the management team appeared to leave at the same time, CFO wrote article touting how valuable she is to clincial stage biotechs, business as usual you say. Or one could argue the signs point to some type of change of control that will be announced soon.
Market Data 
Markets 
AI
